BC
NKTR icon

Bayforest Capital’s Nektar Therapeutics NKTR Stock Holding History

Bayforest Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$183K Sell
2,538
-3
-0.1% -$171 0.2% 148
2025
Q4 		$107K Buy
2,541
+862
+51% +$48.2K 0.08% 449
2025
Q3 		$95.5K Buy
+1,679
New +$55.6K 0.05% 531

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bayforest Capital's NKTR Position: Q1 2026 in Review

Bayforest Capital reduced its Nektar Therapeutics (NKTR) stake by 0.12% in Q1 2026, selling an estimated $171 and leaving 2,538 shares worth $183K. The position accounts for 0.2% of the portfolio, ranked #148.

Bayforest Capital first reported a position in NKTR in Q3 2025 and has held it in 3 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Bayforest Capital held 2,538 shares of Nektar Therapeutics worth $183K as of Q1 2026.
  • Bayforest Capital sold 3 Nektar Therapeutics shares in Q1 2026, an estimated $171.
  • Nektar Therapeutics made up 0.2% of Bayforest Capital's portfolio in Q1 2026, its #148 holding.
  • Bayforest Capital first reported a position in Nektar Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Bayforest Capital's 13F filing for Q1 2026, filed 15 Apr 2026.